Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy. Pharmaceutical stocks—and hea ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

As you can see from the chart above the percentage of shares that are sold short for Amgen has declined since its last report. This does not mean that the stock is going to rise in the near-term ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average. Supported by world-class markets data from ...

Amgen (AMGN) closed at $311.55 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 0.55%. Elsewhere, the Dow gained 1.01%, while ...

The latest trading session saw Amgen (AMGN) ending at $310.09, denoting a +1.44% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 4.84%.

With a market cap of $149.1 billion, Amgen Inc. (AMGN) is renowned for its innovative human therapeutics across oncology, cardiovascular, inflammation, bone health, and nephrology. With a robust ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs deemed unaffordable in Colorado, finding that the maker of arthritis ...